Genetic variability in hepatitis C virus and its role in antiviral treatment response

Journal of Viral Hepatitis

Volumn 15, Issue 3, 2008, Pages 188-199

  Torres Puente, M ^a   Cuevas, J M ^a,b   Jimenez Hernandez N ^a,b   Bracho, M A ^a,b   Garcia Robles I ^a   Wrobel, B ^a   Carnicer, F ^c   Del Olmo, J ^d   Ortega, E ^e   Moya, A ^a,b   Gonzalez Candelas F ^a,b  

^a UNIVERSITY OF VALENCIA   (Spain)

^b CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^c HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^d HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^e HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

Author keywords

Alpha interferon; Haplotype diversity; Nucleotide diversity; Ribavirin

Indexed keywords

ALPHA INTERFERON; AMINO ACID; GLYCOPROTEIN E1; GLYCOPROTEIN E2; INTERFERON; NONSTRUCTURAL PROTEIN 5A; RIBAVIRIN;

AMINO ACID COMPOSITION; ANTIVIRAL THERAPY; ARTICLE; CHEMOSENSITIVITY; CORRELATION COEFFICIENT; DRUG TREATMENT FAILURE; GENETIC VARIABILITY; GENOME; GENOTYPE; HAPLOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HOST; HUMAN; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DOMAIN; SEQUENCE ANALYSIS; TREATMENT RESPONSE; UNINDEXED SEQUENCE; VIRAL GENETICS;

AMINO ACID SUBSTITUTION; ANTIVIRAL AGENTS; CONSERVED SEQUENCE; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERON-ALPHA; MOLECULAR SEQUENCE DATA; MUTATION, MISSENSE; RIBAVIRIN; RNA, VIRAL; SEQUENCE ANALYSIS, DNA; VIRAL ENVELOPE PROTEINS; VIRAL NONSTRUCTURAL PROTEINS;

EID: 38549128753     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2007.00929.x     Document Type: Article

References (48)

1. Wasley A, Alter MJ. Epidemiology of hepatitis C: geographic differences and temporal trends. Semin Liver Dis 2000 20 (1 1 16.
2. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005 5 (9 558 567.
3. Dienstag JL, McHutchison JG. American Gastroenterological Association technical review on the management of hepatitis C. Gastroenterology 2006 130 (1 231 264.
4. Heathcote J, Main J. Treatment of hepatitis C. J Viral Hep 2005 12 (3 223 235.
5. Afdhal NH. The natural history of hepatitis C. Semin Liver Dis 2004 24 (Suppl. 2 3 8.
6. Lindenbach BD, Rice CM. Unravelling hepatitis C virus replication from genome to function. Nature 2005 436 (7053 933 938.
7. Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001 358 (9286 958 965.
8. Fried MW, Shiffman ML, Reddy KR et al. Peginterferon a-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002 347 (13 975 982.
9. Hadziyannis SJ, Sette Jr. H, Morgan TR et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004 140 : 346 355.
10. Zeuzem S, Hulcrantz R, Bourliere M et al. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol 2004 40 : 993 999.
11. Bukh J, Miller RH, Purcell RH. Genetic heterogeneity of hepatitis C virus: quasispecies and genotypes. Semin Liver Dis 1995 15 : 41 63.
12. Weiner AJ, Geysen HM, Christopherson C et al. Evidence for immune selection of hepatitis C virus (HCV) putative envelope glycoprotein variants: potential role in chronic HCV infections. Proc Natl Acad Sci USA 1992 89 (8 3468 3472.
13. Kato N, Sekiya H, Ootsuyama Y et al. Humoral immune response to hypervariable region 1 of the putative envelope glycoprotein (gp70) of hepatitis C virus. J Virol 1993 67 (7 3923 3930.
14. Taniguchi S, Okamoto H, Sakamoto M et al. A structurally flexible and antigenically variable N-terminal domain of the hepatitis C virus E2/NS1 protein: implication for an escape from antibody. Virology 1993 195 (1 297 301.
15. Farci P, Shimoda A, Coiana A et al. The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. Science 2000 288 : 339 344.
16. Manzin A, Solforosi L, Petrelli E et al. Evolution of hypervariable region 1 of hepatitis C virus in primary infection. J Virol 1998 72 (7 6271 6276.
17. Ray SC, Wang YM, Laeyendecker O, Ticehurst JR, Villano SA, Thomas DL. Acute hepatitis C virus structural gene sequences as predictors of persistent viremia: hypervariable region 1 as a decoy. J Virol 1999 73 (4 2938 2946.
18. Chang KM, Rehermann B, McHutchison JG et al. Immunological significance of cytotoxic T lymphocyte epitope variants in patients chronically infected by the hepatitis C virus. J Clin Invest 1997 100 : 2376 2385.
19. Mondelli MU, Cerino A, Segagni L et al. Hypervariable region 1 of hepatitis C virus: immunological decoy or biologically relevant domain? Antiviral Res 2001 52 (2 153 159.
20. Reed KE, Rice CM. Overview of hepatitis C virus genome structure, polyprotein processing, and protein properties. Curr Top Microbiol Immunol 2000 242 : 55 84.
21. Farci P, Strazzera R, Alter HJ et al. Early changes in hepatitis C viral quasispecies during interferon therapy predict the therapeutic outcome. Proc Natl Acad Sci USA 2002 99 (5 3081 3086.
22. Okamoto H, Kojima M, Okada S. Genetic drift of hepatitis C virus during an 8.2-year infection in a chimpanzee: variability and stability. Virology 1992 190 : 894 899.
23. Farci P, Purcell RH. Clinical significance of hepatitis C virus genotypes and quasispecies. Semin Liver Dis 2000 20 (1 103 126.
24. Curran R, Jameson CL, Craggs JK et al. Evolutionary trends of the first hypervariable region of the hepatitis C virus E2 protein in individuals with differing liver disease severity. J Gen Virol 2002 83 (1 11 23.
25. Penin F, Combet C, Germanidis G, Frainais PO, Deleage G, Pawlotsky JM. Conservation of the conformation and positive charges of hepatitis C virus E2 envelope glycoprotein hypervariable region 1 points to a role in cell attachment. J Virol 2001 75 (12 5703 5710.
26. Gale MJ, Korth MJ, Tang NM et al. Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein. Virology 1997 230 (2 217 227.
27. Gale Jr. MJ, Korth MJ, Katze MG. Repression of the PKR protein kinase by the hepatitis C virus NS5A protein: a potential mechanism of interferon resistance. Clin Diagn Virol 1998 10 (2-3 157 162.
28. Duverlie G, Khorsi H, Castelain S et al. Sequence analysis of the NS5A protein of European hepatitis C virus 1b isolates and relation to interferon sensitivity. J Gen Virol 1998 79 : 1373 1381.
29. Durante ME, Forton DM, Ruggiero G, Karayiannis P. Hepatitis C virus E2 and NS5A region variability during sequential treatment with two interferon-alpha preparations. J Med Virol 2003 70 (1 62 73.
30. Ohno O, Mizokami M, Wu RR et al. New hepatitis C virus (HCV) genotyping system that allows for identification of HCV genotypes 1a, 1b, 2a, 2b, 3a, 3b, 4, 5a, and 6a. J Clin Microbiol 1997 35 (1 201 207.
31. Jiménez-Hernández N, Torres-Puente M, Bracho MA et al. Epidemic dynamics of two coexisting hepatitis C virus subtypes. J Gen Virol 2007 88 (1 123 133.
32. Bracho MA, García-Robles I, Jiménez N, Torres-Puente M, Moya A, González-Candelas F. Effect of oligonucleotide primers in determining viral variability within hosts. Virol J 2004 1 : 13.
33. Thompson JD, Gibson TJ, Plewniak F, Jeanmougin F, Higgins DG. The CLUSTAL_X windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools. Nucl Acids Res 1997 25 (24 4876 4882.
34. Rozas J, Sanchez-DelBarrio JC, Messeguer X, Rozas R. DnaSP, DNA polymorphism analyses by the coalescent and other methods. Bioinformatics 2003 19 (18 2496 2497.
35. Korber B, Myers G. Signature pattern analysis: a method for assessing viral sequence relatedness. AIDS Res Hum Retroviruses 1992 8 (9 1549 1560.
36. Sokal RR, Rohlf FJ. Biometry: The Principles and Practice of Statistics in Biological Research, 3rd edn. New York : W.H. Freeman & Co., 1995.
37. Torres-Puente M, Cuevas JM, Jiménez N et al. The contribution of insertions and deletions to the variability of hepatitis C virus populations. J Gen Virol 2007 88 : 2198 2203.
38. Shindo M, Hamada K, Koya S, Arai K, Sokawa Y, Okuno T. The clinical significance of changes in genetic heterogeneity of the hypervariable region 1 in chronic hepatitis C with interferon therapy. Hepatology 1996 24 (5 1018 1023.
39. Polyak SJ, Faulkner G, Carithers Jr. RL, Corey L, Gretch DR. Assessment of hepatitis C virus quasispecies heterogeneity by gel shift analysis: correlation with response to interferon therapy. J Infect Dis 1997 175 (5 1101 1107.
40. Pawlotsky JM, Germanidis G, Frainais P et al. Evolution of the hepatitis C virus second envelope protein hypervariable region in chronically infected patients receiving alpha interferon therapy. J Virol 1999 73 (8 6490 6499.
41. Troesch M, Meunier I, Lapierre P et al. Study of a novel hypervariable region in hepatitis C virus (HCV) E2 envelope glycoprotein. Virology 2006 352 (2 357 367.
42. Polyak SJ, Paschal DM, McArdle S, Gale Jr. MJ, Moradpour D, Gretch DR. Characterization of the effects of hepatitis C virus nonstructural 5A protein expression in human cell lines and on interferon-sensitive virus replication. Hepatology 1999 29 (4 1262 1271.
43. Liang TJ, Rehermann B, Seeff LB, Hoofnagle JH. Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann Intern Med 2000 132 (4 296 305.
44. Pawlotsky JM. Therapy of hepatitis C: from empiricism to eradication. Hepatology 2006 43 (2 Suppl. 1 S207 S220.
45. Sheridan I, Pybus OG, Holmes EC, Klenerman P. High resolution phylogenetic analysis of hepatitis C virus adaptation and its relationship to disease progression. J Virol 2004 78 (7 3447 3454.
46. Stumpf MPH, Pybus OG. Genetic diversity and models of viral evolution for the hepatitis C virus. FEMS Microbiol Lett 2002 214 : 143 152.
47. Bocharov G, Klenerman P, Ehl S. Modelling the dynamics of LCMV infection in mice. II. Compartmental structure and immunopathology. J Theor Biol 2003 221 : 349 378.
48. Yagnik AT, Lahm A, Meola A, Roccasecca RM, Ercole BB, Nicosia A. A model for the hepatitis C virus envelope glycoprotein E2. Proteins 2000 40 (3 355 366.